{"id":"https://openalex.org/W2052494740","doi":"https://doi.org/10.1002/cncr.22528","title":"Association between pharmaceutical involvement and outcomes in breast cancer clinical trials","display_name":"Association between pharmaceutical involvement and outcomes in breast cancer clinical trials","publication_year":2007,"publication_date":"2007-02-26","ids":{"openalex":"https://openalex.org/W2052494740","doi":"https://doi.org/10.1002/cncr.22528","mag":"2052494740","pmid":"https://pubmed.ncbi.nlm.nih.gov/17326054"},"language":"en","primary_location":{"id":"doi:10.1002/cncr.22528","doi":"https://doi.org/10.1002/cncr.22528","is_oa":false,"landing_page_url":"https://doi.org/10.1002/cncr.22528","pdf_url":null,"source":{"id":"https://openalex.org/S126033908","display_name":"Cancer","issn_l":"0008-543X","issn":["0008-543X","1045-7410","1097-0142"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5010429902","display_name":"Jeffrey M. Peppercorn","orcid":"https://orcid.org/0000-0001-7138-6404","observed_orcids":["https://orcid.org/0000-0001-7138-6404"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Jeffrey Peppercorn","raw_affiliation_strings":["Division of Hematology/Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA. jpepper@med.unc.edu","Division of Hematology/Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina","Jeffrey Peppercorn is a member of the Speakers Bureau for Genentech and is a consultant for Merck"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology/Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA. jpepper@med.unc.edu","institution_ids":["https://openalex.org/I114027177"]},{"raw_affiliation_string":"Division of Hematology/Oncology, University of North Carolina School of Medicine, Chapel Hill, North Carolina","institution_ids":["https://openalex.org/I114027177"]},{"raw_affiliation_string":"Jeffrey Peppercorn is a member of the Speakers Bureau for Genentech and is a consultant for Merck","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111968600","display_name":"Emily Blood","orcid":"https://orcid.org/0000-0003-4086-4578","observed_orcids":["https://orcid.org/0000-0003-4086-4578","https://orcid.org/0000-0002-6166-4455"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Emily Blood","raw_affiliation_strings":["Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070245248","display_name":"Eric P. Winer","orcid":"https://orcid.org/0000-0002-8819-1723","observed_orcids":["https://orcid.org/0000-0002-8819-1723"]},"institutions":[{"id":"https://openalex.org/I3018075036","display_name":"Sanofi (France)","ror":"https://ror.org/02n6c9837","country_code":"FR","type":"company","lineage":["https://openalex.org/I3018075036"]},{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["FR","US"],"is_corresponding":false,"raw_author_name":"Eric Winer","raw_affiliation_strings":["Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts","Eric Winer is a consultant for GlaxoSmithKline, Bristol-Meyers Squibb, Sanofi-Aventis, Boerringer-Ingleheim, Berlex, Genomic Health, Genentech, Wyeth, Pfizer, and Astra Zeneca and receives research funding for clinical trials from Genentech, GlaxoSmithKline, Astra Zeneca, and Pfizer"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]},{"raw_affiliation_string":"Eric Winer is a consultant for GlaxoSmithKline, Bristol-Meyers Squibb, Sanofi-Aventis, Boerringer-Ingleheim, Berlex, Genomic Health, Genentech, Wyeth, Pfizer, and Astra Zeneca and receives research funding for clinical trials from Genentech, GlaxoSmithKline, Astra Zeneca, and Pfizer","institution_ids":["https://openalex.org/I3018075036"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5039694693","display_name":"Ann H. Partridge","orcid":"https://orcid.org/0000-0002-4722-4824","observed_orcids":["https://orcid.org/0000-0002-4722-4824"]},"institutions":[{"id":"https://openalex.org/I4210117453","display_name":"Dana-Farber Cancer Institute","ror":"https://ror.org/02jzgtq86","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210117453"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ann Partridge","raw_affiliation_strings":["Ann Partridge is a consultant for Astra Zeneca","Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ann Partridge is a consultant for Astra Zeneca","institution_ids":[]},{"raw_affiliation_string":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts","institution_ids":["https://openalex.org/I4210117453"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5010429902"],"corresponding_institution_ids":["https://openalex.org/I114027177"],"apc_list":{"value":4790,"currency":"USD","value_usd":4790},"apc_paid":null,"fwci":24.3732,"has_fulltext":false,"cited_by_count":124,"citation_normalized_percentile":{"value":0.99313787,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"109","issue":"7","first_page":"1239","last_page":"1246"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11649","display_name":"Pharmaceutical industry and healthcare","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2910","display_name":"Issues, ethics and legal aspects"},"field":{"id":"https://openalex.org/fields/29","display_name":"Nursing"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11649","display_name":"Pharmaceutical industry and healthcare","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2910","display_name":"Issues, ethics and legal aspects"},"field":{"id":"https://openalex.org/fields/29","display_name":"Nursing"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12816","display_name":"Global Public Health Policies and Epidemiology","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12225","display_name":"Political Influence and Corporate Strategies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1408","display_name":"Strategy and Management"},"field":{"id":"https://openalex.org/fields/14","display_name":"Business, Management and Accounting"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pharmaceutical-industry-sponsorship","display_name":"pharmaceutical industry sponsorship","score":0.7879999876022339},{"id":"https://openalex.org/keywords/breast-cancer-clinical-trials","display_name":"breast cancer clinical trials","score":0.9539999961853027},{"id":"https://openalex.org/keywords/conflict-of-interest","display_name":"conflicts of interest","score":0.6880000233650208},{"id":"https://openalex.org/keywords/trial-design","display_name":"trial design","score":0.4779999852180481},{"id":"https://openalex.org/keywords/single-arm-studies","display_name":"single-arm studies","score":0.531000018119812},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.9919999837875366},{"id":"https://openalex.org/keywords/research-funding-sources","display_name":"research funding sources","score":0.6430000066757202}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8164902925491333},{"id":"https://openalex.org/C2779652045","wikidata":"https://www.wikidata.org/wiki/Q507443","display_name":"Pharmaceutical industry","level":2,"score":0.7262168526649475},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.6445485353469849},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5994047522544861},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.5499175190925598},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.5276792645454407},{"id":"https://openalex.org/C2777276634","wikidata":"https://www.wikidata.org/wiki/Q211067","display_name":"Conflict of interest","level":2,"score":0.42639344930648804},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3498678207397461},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.21006610989570618},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.20352739095687866},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.1370956003665924},{"id":"https://openalex.org/C162324750","wikidata":"https://www.wikidata.org/wiki/Q8134","display_name":"Economics","level":0,"score":0.0},{"id":"https://openalex.org/C10138342","wikidata":"https://www.wikidata.org/wiki/Q43015","display_name":"Finance","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000191","qualifier_name":"economics","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D001319","descriptor_name":"Authorship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":"Q000639","qualifier_name":"trends","is_major_topic":true},{"descriptor_ui":"D004341","descriptor_name":"Drug Evaluation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004345","descriptor_name":"Drug Industry","qualifier_ui":"Q000639","qualifier_name":"trends","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011643","descriptor_name":"Publishing","qualifier_ui":"Q000639","qualifier_name":"trends","is_major_topic":true},{"descriptor_ui":"D012109","descriptor_name":"Research Support as Topic","qualifier_ui":"Q000639","qualifier_name":"trends","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D035843","descriptor_name":"Biomedical Research","qualifier_ui":"Q000639","qualifier_name":"trends","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1002/cncr.22528","doi":"https://doi.org/10.1002/cncr.22528","is_oa":false,"landing_page_url":"https://doi.org/10.1002/cncr.22528","pdf_url":null,"source":{"id":"https://openalex.org/S126033908","display_name":"Cancer","issn_l":"0008-543X","issn":["0008-543X","1045-7410","1097-0142"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer","raw_type":"journal-article"},{"id":"pmid:17326054","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17326054","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.5683000087738037,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":26,"referenced_works":["https://openalex.org/W1585928332","https://openalex.org/W1970259524","https://openalex.org/W1985484857","https://openalex.org/W2016300030","https://openalex.org/W2020830322","https://openalex.org/W2023482608","https://openalex.org/W2025631053","https://openalex.org/W2048504229","https://openalex.org/W2053664176","https://openalex.org/W2056651344","https://openalex.org/W2087081233","https://openalex.org/W2101881391","https://openalex.org/W2106787323","https://openalex.org/W2109694492","https://openalex.org/W2112339576","https://openalex.org/W2123340665","https://openalex.org/W2142969636","https://openalex.org/W2149843684","https://openalex.org/W2157531023","https://openalex.org/W2169698098","https://openalex.org/W2183582392","https://openalex.org/W2318605753","https://openalex.org/W2337821671","https://openalex.org/W2461165450","https://openalex.org/W2499596741","https://openalex.org/W4230230404"],"related_works":["https://openalex.org/W2247944615","https://openalex.org/W2162220769","https://openalex.org/W2589744990","https://openalex.org/W4399123749","https://openalex.org/W2150725735","https://openalex.org/W2169698098","https://openalex.org/W2439872067","https://openalex.org/W2031244707","https://openalex.org/W2732385679","https://openalex.org/W2789369984"],"abstract_inverted_index":{"BACKGROUND:":[0],"Since":[1],"1992,":[2],"pharmaceutical":[3,71,106,154,164,236,305],"industry":[4,107,155,165,306],"support":[5],"has":[6],"surpassed":[7],"National":[8],"Institutes":[9],"of":[10,30,43,110,180,188,197,209,215,222,296,303],"Health":[11],"funding":[12,34],"for":[13,93,98,114],"clinical":[14,47,54,279,309],"research":[15,282,291],"in":[16,33,131,138,146,178,184,186,192,195,201,207,213,220,231,277],"the":[17,23,28,41,76,181,189,198,210,216,223,301],"United":[18],"States.":[19],"In":[20,118],"this":[21,31],"study,":[22],"authors":[24],"sought":[25],"to":[26,37,69,241,253,264,299],"evaluate":[27,70,265,300],"impact":[29,302],"shift":[32],"from":[35,56,63,90],"public":[36],"private":[38],"sponsors":[39],"on":[40,308],"nature":[42],"published":[44,51,130,137,145,183,191,200,230,278],"breast":[45,52,94,280],"cancer":[46,53,95,281],"research.":[48,310],"METHODS:":[49],"All":[50],"trials":[55],"2003,":[57,232],"1998,":[58,139,193],"and":[59,75,82,140,194,219,263,288],"1993":[60,211],"were":[61,96,123,129,136,144,171,229,238],"reviewed":[62],"10":[64],"select":[65],"English-language":[66],"medical":[67,91],"journals":[68],"involvement":[72,101,175,237,276,307],"over":[73],"time":[74],"association":[77],"between":[78],"sponsorship,":[79],"trial":[80],"design,":[81,286],"results.":[83,289],"Clinical":[84],"studies":[85,122,127,134,142,182,190,199,227,256],"that":[86,128,135,143,228,234],"reported":[87,105,153,206,235],"disease-specific":[88],"outcomes":[89],"therapy":[92],"eligible":[97,121],"analysis.":[99],"Pharmaceutical":[100,174,203,275],"was":[102,176,205],"defined":[103],"as":[104],"funding,":[108],"provision":[109],"drug,":[111],"and/or":[112],"authorship":[113,204],"each":[115],"publication.":[116],"RESULTS:":[117],"total,":[119],"140":[120],"identified,":[124],"including":[125,294],"45":[126],"1993,":[132,185],"39":[133],"56":[141],"2003.":[147,202],"Among":[148],"those,":[149],"67":[150],"publications":[151,158,169],"(48%)":[152],"involvement,":[156],"36":[157],"(26%)":[159],"had":[160],"at":[161],"least":[162],">/=1":[163],"author,":[166],"And":[167],"100":[168],"(71%)":[170],"considered":[172],"positive.":[173],"identified":[177],"44%":[179],"38%":[187],"58%":[196],"22%":[208],"studies,":[212,218,298],"21%":[214],"1998":[217],"34%":[221],"2003":[224],"studies.":[225],"For":[226],"those":[233],"more":[239],"likely":[240],"be":[242,254],"positive":[243],"(84%":[244],"vs":[245,258,269],"54%;":[246],"P":[247,260,271],"=":[248,261,272],".02;":[249],"Fisher":[250],"exact":[251],"test),":[252],"single-arm":[255],"(66%":[257],"33%;":[259],".03),":[262],"metastatic":[266],"disease":[267],"(72%":[268],"46%;":[270],".06).":[273],"CONCLUSIONS:":[274],"may":[283],"affect":[284],"study":[285],"focus,":[287],"Further":[290],"is":[292],"warranted,":[293],"analysis":[295],"unpublished":[297],"increasing":[304]},"counts_by_year":[{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":6},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":6},{"year":2017,"cited_by_count":5},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":7},{"year":2014,"cited_by_count":8},{"year":2013,"cited_by_count":7},{"year":2012,"cited_by_count":8}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2016-06-24T00:00:00"}